Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window

Molecular Cancer Therapeutics

Volumn 5, Issue 1, 2006, Pages 80-88

  Matsunaga, Naoki ^a   Nakamura, Kazuhide ^a   Yamamoto, Atsushi ^a   Taguchi, Eri ^a   Tsunoda, Hiromi ^a   Takahashi, Kazumi ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KRN 633; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; CARBANILAMIDE DERIVATIVE; N (2 CHLORO 4 ((6,7 DIMETHOXY 4 QUINAZOLINYL)OXY)PHENYL) N' PROPYLUREA; N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINAZOLINYL)OXY)PHENYL)-N'-PROPYLUREA; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CRYSTALLIZATION; DENSITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; EXPERIMENTAL NEOPLASM; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; TUMOR VASCULARIZATION; WEIGHT REDUCTION; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; BLOOD VESSEL; BODY WEIGHT; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BLOOD VESSELS; BODY WEIGHT; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644851073     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0202     Document Type: Article

References (25)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
2. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27.
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
7. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
8. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
9. Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003;63:5978-91.
10. Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63: 7301-9.
11. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
12. Sepp-Lorenzino L, Rands E, Mao X, et al. A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res 2004;64: 751-6.
13. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65: 4389-400.
14. Nakamura K, Yamamoto A, Kamishohara M, et al. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 2004;3:1639-49.
15. Goldberg AH, Gibaldi M, Kanig JL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature. J Pharm Sci 1965;54:1145-8.
16. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302.
17. Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058-66.
18. Shah N, Pytelewski R, Eisen H, Jarowski CI. Influence of dispersion method on dissolution rate and bioavailability of digoxin from triturations and compressed tablets II. J Pharm Sci 1974;63:339-44.
19. Kushida I, Ichikawa M, Asakawa N. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci 2002;91:258-66.
20. Yamashita K, Nakate T, Okimoto K, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003;267:79-91.
21. Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm 2004;282:151-62.
22. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004; 10:4258-62s.
23. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997;99:2351-7.
24. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999;104:913-23.
25. Masuda Y, Shimizu A, Mori T, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001;159: 599-608.